Breathing Harder, Adding Less: Sequencing Therapy in HFrEF with Borderline Potassium
68-year-old man with ischemic cardiomyopathy (LVEF 30% on echocardiography 4 months ago) attends follow-up. He reports dyspnea after two blocks but no resting symptoms. Medications: sacubitril-valsartan 97/103 mg twice daily, carvedilol 12.5 mg twice daily, furosemide 40 mg daily, atorvastatin 40 mg, apixaban for atrial fibrillation. BP 118/70 mmHg, HR 78 and irregular. Today: potassium 5.1 mEq/L, creatinine 1.9 mg/dL (eGFR 36 mL/min/1.73 m²), sodium 136 mEq/L. ECG: atrial fibrillation with a left bundle branch block, QRS 156 ms. He has completed 4 months of neurohormonal therapy that has been tolerated without dose changes for the last 8 weeks. He asks about "the defibrillator my brother got."
1. Apart from his current regimen, which two medication additions have the strongest rationale, and how does a potassium of 5.1 mEq/L shape the order in which you introduce them?
Read the worked answer
Agents to add: an SGLT2 inhibitor and a mineralocorticoid receptor antagonist (MRA).
- SGLT2 inhibitor first (dapagliflozin 10 mg daily). Benefit in HFrEF is independent of diabetes, and his eGFR of 36 is above the threshold for initiating therapy (≥25). Expect a small, non-progressive creatinine rise. A practical bonus is that SGLT2 inhibitors modestly lower potassium and reduce hyperkalemia risk, which makes subsequent MRA use safer.
- Then an MRA (spironolactone 12.5 mg or eplerenone 25 mg). Potassium 5.1 with eGFR 36 is a borderline but not prohibitive starting point; both values sit near, not beyond, accepted thresholds (K <5.0–5.5, eGFR >30). Start low, hold potassium supplements and salt substitutes, avoid NSAIDs and trimethoprim, and recheck potassium and creatinine at 1 and 4 weeks.
Sequencing logic: give the SGLT2 inhibitor now, recheck potassium in 1–2 weeks, then add the MRA if potassium is ≤5.0–5.2. If potassium cannot be kept below 5.5, a potassium binder allows the MRA to continue rather than be abandoned, since the mortality benefit is substantial.
2. Does this patient warrant a cardiac device now? Justify the specific device and address the one feature of his case that complicates the decision.
Read the worked answer
He warrants a CRT-D (biventricular pacemaker-defibrillator), not an ICD alone.
Criteria met:
- LVEF ≤35% that has persisted despite ≥3 months of tolerated guideline-directed medical therapy.
- Left bundle branch block with QRS ≥150 ms (his is 156 ms).
- Ambulatory NYHA class II symptoms.
- Expected survival beyond 1 year with good functional status.
LBBB with QRS ≥150 ms is the subgroup that gains the most from cardiac resynchronization, so biventricular pacing should be part of the device rather than leaving him with a shock-only ICD.
The complicating feature is his atrial fibrillation. CRT benefit depends on a high percentage of biventricular-paced beats; with AF and an irregular rate, intrinsic conduction can blunt resynchronization. Confirm rate control, and if biventricular pacing remains low, AV nodal ablation is a reasonable adjunct. Before implanting, repeat echocardiography to confirm EF is still ≤35% after 4 months of therapy, and discuss goals, shock burden, and the possibility that EF recovery could change the decision.
3. Two weeks after starting the MRA, potassium is 5.7 mEq/L and he has had 2 days of diarrhea. Outline your management.
Read the worked answer
This is a precipitating-event hyperkalemia, not proof that MRAs must be abandoned.
- Hold the MRA immediately and stop any potassium supplement, salt substitute, NSAID, or trimethoprim-containing antibiotic. Obtain an ECG and repeat potassium to exclude hemolysis-related pseudohyperkalemia.
- Treat the volume and electrolyte problem: the diarrhea is causing both intravascular depletion and reduced distal sodium delivery, which impairs potassium excretion. Give isotonic saline if he is hypovolemic, and recheck creatinine and potassium in 4–6 hours. Temporarily hold the SGLT2 inhibitor during acute illness with poor intake to avoid euglycemic ketoacidosis, and restart when eating normally.
- When potassium is <5.0 and the diarrhea has resolved, rechallenge the MRA at a lower dose, ideally with a potassium binder (patiromer or sodium zirconium cyclosilicate) started concurrently, and repeat potassium at 1 week.
- Only abandon MRA therapy if hyperkalemia recurs despite dose reduction, dietary review, and a binder, or if kidney function deteriorates further.